Here's the full evidence picture — and the significant gaps that remain. Historical articles may no longer reflect current regulatory status. Check the cited primary source.
MOTS-c is encoded in mitochondrial DNA. It is a 16-amino-acid peptide that declines with age. In aged mice, it improves physical performance, reverses insulin resistance, and trends toward increased lifespan.
HHS proposed 503A enforcement discretion (not final). FDA substance context: MOTS-c. Named in the proposed HHS 503A enforcement-discretion notice (Federal Register 2026-22192, October 2026). The policy is proposed, not final, and is not FDA approval. FDA's earlier record lists the nomination as withdrawn from Category 2 with potential significant safety risks. Regulatory source checked October 29, 2026. Sources: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
This tension — a biologically compelling compound with a significant evidence gap and active regulatory restriction — is exactly what PeptideX's evidence tier system is designed to capture.
MOTS-c (Mitochondrial Open-reading-frame of the twelve S rRNA type-c) is encoded in the 12S rRNA region of the mitochondrial genome — making it one of a small class of mitochondria-derived peptides (MDPs). Under metabolic stress conditions, MOTS-c translocates from mitochondria to the cell nucleus, where it regulates gene expression via the AMPK and NRF2 pathways.
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy
Key functions documented in preclinical research:
A landmark 2021 Nature Communications study from the Lee lab at USC showed that MOTS-c treatment in aged mice improved grip strength, gait, and physical performance — and enabled old mice to outperform untreated middle-aged mice on treadmill tests. The lifespan data trended positive but did not reach statistical significance with the cohort sizes used.
No completed human trials. Observational data shows declining circulating levels with age. All therapeutic claims are extrapolated from preclinical models — a translation that has failed repeatedly in longevity biology.
Strong mechanistic story. No human data. See the dated source-linked regulatory context. Confidence ceiling is hard at 2 until human pharmacokinetic and safety data exists.
Full compound profile: peptidex.ai/compounds/mots-c
*This content is for educational and informational purposes only. Not medical advice. See full Research Disclaimer.*
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy